These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia. Kowalec K; Kingwell E; Carruthers R; Marrie RA; Bernatsky S; Traboulsee A; Ross CJD; Carleton B; Tremlett H BMJ Open; 2017 Jun; 7(5):e016276. PubMed ID: 28576902 [TBL] [Abstract][Full Text] [Related]
4. New onset lymphopenia in patients with relapsing multiple sclerosis switching from long-standing dimethyl fumarate treatment to diroximel fumarate: A case series. Schneider M; Kramer J; Banks A; Moses H Mult Scler; 2024 Sep; 30(10):1379-1382. PubMed ID: 38605496 [TBL] [Abstract][Full Text] [Related]
5. CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient. Kogel AK; Gold R; Schneider R J Neurol; 2021 Nov; 268(11):4374-4375. PubMed ID: 34175973 [No Abstract] [Full Text] [Related]
6. The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk. Khatri BO; Garland J; Berger J; Kramer J; Sershon L; Olapo T; Sesing J; Dukic M; Rehn E Mult Scler Relat Disord; 2015 Jul; 4(4):377-9. PubMed ID: 26195059 [TBL] [Abstract][Full Text] [Related]
7. Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient. Perini P; Rinaldi F; Puthenparampil M; Marcon M; Perini F; Gallo P Mult Scler Relat Disord; 2018 Nov; 26():68-70. PubMed ID: 30227312 [TBL] [Abstract][Full Text] [Related]
8. Diffuse dermatophytosis occurring on dimethyl fumarate therapy. Greenstein JI Mult Scler; 2018 Jun; 24(7):999-1001. PubMed ID: 29649923 [TBL] [Abstract][Full Text] [Related]
9. Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate. Wood CH; Robertson NP; Htet ZM; Tallantyre EC Mult Scler Relat Disord; 2022 Feb; 58():103492. PubMed ID: 35066268 [TBL] [Abstract][Full Text] [Related]
10. Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation. Caldito NG; O'Leary S; Stuve O Mult Scler; 2021 Jul; 27(8):1306-1308. PubMed ID: 33620273 [TBL] [Abstract][Full Text] [Related]
11. Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients. Jordan AL; Yang J; Fisher CJ; Racke MK; Mao-Draayer Y Mult Scler; 2022 Jan; 28(1):7-15. PubMed ID: 32808554 [TBL] [Abstract][Full Text] [Related]
12. Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis. Luo H; Bhatt H; Mohamad S; Uhrik E; Sen S; Mathew T; Yousif A J Neurol; 2015 Mar; 262(3):779-80. PubMed ID: 25626723 [No Abstract] [Full Text] [Related]
13. Bariatric surgery and dimethyl fumarate-induced lymphopenia in patients with multiple sclerosis. Andreozzi V; Capuano R; Scannapieco S; Barra F; d'Arco B; Giordano C; Caterino M; De Marca U; Di Filippo F; Di Gregorio M; Barone P Neurol Sci; 2024 Jun; 45(6):2807-2810. PubMed ID: 38150132 [TBL] [Abstract][Full Text] [Related]
14. Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment. Garbo R; Lorenzut S; Del Negro I; Merlino G; Gigli GL; Cargnelutti D; Valente M Mult Scler Relat Disord; 2021 Apr; 49():102781. PubMed ID: 33524927 [TBL] [Abstract][Full Text] [Related]
15. Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia. Diebold M; Galli E; Kopf A; Sanderson N; Callegari I; Ingelfinger F; Núñez NG; Benkert P; Kappos L; Kuhle J; Becher B; Claassen M; Derfuss T Ann Neurol; 2022 May; 91(5):676-681. PubMed ID: 35170072 [TBL] [Abstract][Full Text] [Related]
16. Legionella infection associated with dimethyl fumarate used for treatment of multiple sclerosis. Rastas C; Sirignano D; Barner A; Bruno-Murtha LA J Neurol; 2019 Nov; 266(11):2867-2868. PubMed ID: 31350640 [No Abstract] [Full Text] [Related]
17. Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis. Losavio FA; Lucchini M; De Fino C; Mirabella M; Nociti V Mult Scler Relat Disord; 2016 May; 7():68-9. PubMed ID: 27237761 [TBL] [Abstract][Full Text] [Related]
18. Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate. Morales FS; Koralnik IJ; Gautam S; Samaan S; Sloane JA J Neurol; 2020 Jan; 267(1):125-131. PubMed ID: 31583427 [TBL] [Abstract][Full Text] [Related]
19. Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events. Calabrese M; Pitteri M; Farina G; Bajrami A; Castellaro M; Magliozzi R; Monaco S J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1073-1078. PubMed ID: 28844068 [TBL] [Abstract][Full Text] [Related]
20. Fingolimod-associated PML in a patient with prior immunosuppression. Gyang TV; Hamel J; Goodman AD; Gross RA; Samkoff L Neurology; 2016 May; 86(19):1843-5. PubMed ID: 27164718 [No Abstract] [Full Text] [Related] [Next] [New Search]